← Full daily brief

Startup brief

Cybersecurity and AI Agents Anchor Israeli Early-Stage Rounds

Tel Aviv ventures capture $2.4B in quarterly cyber funding as founders build agent runtime defense, Wall Street plumbing, and chip verification.

Signalpoint TeamBrief

Startup

Capitolis secures equity directly from its Wall Street clients — entrenching its Tel Aviv algorithmic engine as indispensable plumbing for global bank balance sheets.

BackgroundGlobal systemically important banks must maintain stringent statutory capital buffers that limit balance sheet leverage and constrain trading desk profitability. Capitolis operates an institutional marketplace that enables tier-one lenders to optimize and syndicate regulatory capital risk without liquidating client assets.

Points
  1. The funding package combines $120 million in primary equity backed by global investment banks with $100 million in structured debt facilities.
  2. Capitolis generated 65% revenue growth over the past year and expects its marketplace network to achieve sustained operational profitability within 12 months.
  3. The company's core Tel Aviv engineering center will expand automated matching algorithms that help international trading desks compress regulatory risk ratios.

Startup

Surging corporate adoption of autonomous agents creates critical runtime blind spots — handing specialized defense startups like Rein immediate enterprise pricing power.

BackgroundAutonomous software agents execute business tasks by querying enterprise databases and making API calls on behalf of corporate staff. When agents ingest untrusted prompts, attackers can manipulate them into leaking confidential records or executing unauthorized financial transfers.

Points
  1. Rein's inline cloud architecture screens internal code execution in real time, preventing prompt-injection exploits from compromising backend corporate servers.
  2. Founded by military intelligence veterans Matan Bar-Efrat and Netanel Rubin, the startup grew revenue eightfold in 2026 as enterprise agent deployments accelerated.
  3. The Series A round will fund expansion across Tel Aviv and New York engineering hubs to meet strict enterprise compliance standards.

Startup

Global venture capital is concentrating heavily in Tel Aviv — validating Israeli founders as the indispensable architects of enterprise artificial intelligence defense.

BackgroundVenture funding slowed worldwide following central bank rate hikes in 2022, forcing software founders to manage burn rather than chase headcounts. Yet corporate chief information security officers have expanded budgets steadily to neutralize generative AI vulnerabilities and protect cloud infrastructure.

Points
  1. The quarter represented Tel Aviv's strongest cybersecurity funding performance since 2022, propelled by mega-rounds into Cyera, Island, and Upwind at multi-billion-dollar valuations.
  2. Capital concentrated heavily in startups protecting automated software pipelines, enterprise model endpoints, and proprietary cloud data pools from sophisticated automated attacks.
  3. Domestic tech fundraising reached $13.2 billion across 192 rounds through September, demonstrating international investors' continued appetite for Israeli engineering talent despite macro friction.

Startup

Phantom GI replaces traumatic abdominal surgery with a 20-minute needle puncture — giving patients deemed too fragile for surgery a viable clinical path.

BackgroundConventional surgical ostomy procedures require general anesthesia, significant abdominal incisions, and prolonged hospital stays to divert digestive waste outside the body. Critically ill patients suffering from malignant bowel obstructions are frequently disqualified from open surgery due to high surgical mortality risks.

Points
  1. PercStoma replaces invasive bowel resection surgery with a fluoroscopic needle procedure completed in an outpatient setting without general anesthesia.
  2. Seed capital will launch Phase 1 human trials in the United States, targeting terminal cancer patients with no other viable surgical options.
  3. RAD Biomed and RUNI Ventures joined the syndicate to accelerate regulatory clearance applications with the United States Food and Drug Administration.

Startup

Startup

Unlock the full brief

Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.

Or read free in the appDownload on the App Store